Trial Profile
A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN 115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2019
Price :
$35
*
At a glance
- Drugs Tozadenant (Primary) ; Levodopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Biotie Therapies Corp.; UCB
- 08 Jun 2017 Results of a post-hoc analysis from this trial presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 19 Jan 2016 Results published in an Acorda Therapeutics media release.
- 20 Feb 2015 According to Biotie Therapies media release, it expects that the Phase 2b study will be considered the first of two pivotal studies required for registration for tozadenant in PD patients with end-of-dose 'wearing-off'.